SCHEMBL16983077

SCHEMBL16983077

CCOC(=O)NC(=S)Nc1ncc(Br)cc1I

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.50
▸ LMNA P02545 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NPC1 O15118 4/20 0.47
▸ KCNH2 Q12809 2/20 0.47
▸ RAB9A P51151 2/20 0.45
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ GAA P10253 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ AGTR1 P30556 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22585806 0.86 MAPT (0.46) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL26857507 0.82 MAPT (0.45) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL30679687 0.82 MAPT (0.45) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL7853834 0.81 MAPT (0.51) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22585498 0.79 MAPT (0.43) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22585510 0.79 MAPT (0.43) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL30248509 0.79 MAPT (0.43) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL23030187 0.79 MAPT (0.49) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL18952439 0.79 MAPT (0.49) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22558754 0.78 MAPT (0.40) MAPTLMNAPKMSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed
US-20170007615-A1 Antibacterial Compounds SPERO GYRASE, INC. 2017-01-12 — — US disclosed
WO-2015114452-A2 ANTIBACTERIAL COMPOUNDS BIOTA EUROPE LTD (GB) 2015-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170007615-A1 Antibacterial Compounds CLPP, MRPL21, RELA MAPT 4048/4885LMNA 3691/4885PKM 4177/4885
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF SNCA, PSEN2, PARK7 MAPT 13/4885LMNA 2005/4885PKM 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback